SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1878)10/24/2000 10:32:32 AM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Interesting pair of general posts on another thread - note the biotech references:

Message 14637598

and this interesting response:

Message 14642346

Peter



To: Biomaven who wrote (1878)10/24/2000 10:48:21 AM
From: seminole  Respond to of 52153
 
I hope both work too.
I was trying to be nice.

This is not a zero sum game.
We all can win with different picks.



To: Biomaven who wrote (1878)10/24/2000 10:25:01 PM
From: Miljenko Zuanic  Respond to of 52153
 
Peter,

I think that SUPG do have right to all Stehlin F. patents related to CPT.

They are protecting 20-(s)-hydroxyl group as ester, which increase lactone ring stability and cells drug uptake.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News